List view / Grid view
Modelling technique that simultaneously evaluates the effects of possible protein mutations on protein-protein interactions implicated in disease, could cut pre-drug screening time, says research.
Researchers have screened thousands of existing drug molecules against cancer cell lines to discover almost 50 compounds that combat the condition.
Researchers have developed a novel metal-based fragment library of molecules that can be used to screen for new drug candidates.
In an effort to address some of the more serious untreatable infections encountered by patients with cystic fibrosis, Calibr will collaborate with the Cystic Fibrosis Foundation on a two-year project.
Researchers have developed a screening system and identified a set of compounds that protect neuronal mitochondria in mice.
Enzyme Linked Immunosorbent Assays (ELISAs) are one of the most common immunoassays on the market.
Researchers have produced a mathematical framework enabling quick assessment of how different parameters control interactions between molecules with multiple binding sites.
Lab-grown brain organoids from patients’ glioblastomas could be useful models to rapidly test and identify effective personalised treatments, find researchers.
Researchers have developed a luciferase assay that can be used to monitor the effects of treatments on six different molecular targets at once.
Gene editing using the CRISPR system has been established as the most powerful tool in the search for new drugs and is now being exploited for therapeutic purposes. Here, Pushpanathan Muthuirulan discusses the promises and wider opportunities of using CRISPR technology to open up the possibility of large-scale screening of…
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
Chimeric antigen receptor (CAR) T cell transfer has had success as a treatment for leukemia and lymphoma, but solid tumors have been more challenging due to the rarity of true tumor-specific target molecules and the immunosuppressive nature of the tumor microenvironment.
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
Kinase-mediated phosphorylation is a control point for nearly all activity within a cell, making kinases important in many diseases.
In this In-Depth Focus are articles investigating how CROs can help to drive innovation and how CRISPR technologies could be used for drug screening purposes.
